IP Library Granted Patent US 10,017,764
Granted Patent B2
US 10,017,764 · App. 13/984,260 · Granted Jul 10, 2018

Oligomeric compounds comprising bicyclic nucleotides and uses thereof

Inventors: Susan M. Freier (San Diego, CA); Eric E. Swayze (Encinitas, CA)
Assignee: Ionis Pharmaceuticals, Inc.
C12N15/113C12N15/111C12N2310/11C12N2310/315C12N2310/3231C12N2310/341C12N2310/346
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,017,764
App. No.
13/984,260
Granted
Jul 10, 2018
Kind
B2
Abstract

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Claims (15)

1. A compound comprising:

a modified oligonucleotide consisting of 19 or 20 linked nucleosides, wherein the modified oligonucleotide comprises:

a 5′-wing comprising a BABBB motif, a BBABB motif, a BABAB motif, a BBAAB motif, a BAABB motif, or a BBBAB motif, wherein the 3′-most 5′-wing nucleoside is a bicyclic nucleoside;

a 3′-wing comprising a BABBB motif, a BAABB motif, a BBAAB motif, a BABAB motif, or a BBABB motif, wherein the 5′-most 3′-wing nucleoside is a bicyclic nucleoside; and

a gap between the 5′-wing and the 3′-wing consisting of 9 or 10 linked 2′-deoxynucleosides; and

wherein each B is a bicyclic nucleoside and each A is a 2′-deoxynucleoside and the modified oligonucleotide does not comprise a non-bicyclic 2′-substituted nucleoside.

2. The compound of claim 1 , wherein the gap consists of 9 linked 2′-deoxynucleosides.

3. The compound of claim 1 , wherein the gap consists of 10 linked 2′-deoxynucleosides.

4. The compound of claim 1 , wherein the 5′ wing comprises a BABBB motif and the 3′ wing comprises a BBABB motif.

5. The compound of claim 1 , wherein the 5′ wing comprises a BBABB motif and the 3′ wing comprises a BBABB motif.

6. The compound of claim 1 , wherein the 5′ wing comprises a BBBAB motif and the 3′ wing comprises a BABAB motif.

7. The compound of claim 1 , wherein each bicyclic nucleoside is a locked nucleic acid (LNA) nucleoside.

8. The compound of claim 4 , wherein each bicyclic nucleoside is a locked nucleic acid (LNA) nucleoside.

9. The compound of claim 5 , wherein each bicyclic nucleoside is a locked nucleic acid (LNA) nucleoside.

10. The compound of claim 6 , wherein each bicyclic nucleoside is a locked nucleic acid (LNA) nucleoside.

Assignments (1)
CHANGE OF NAME Recorded Feb 23, 2016
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 037893/0477 →
Continuity (4)
Provisional Application 61440828 · Feb 8, 2011
Provisional Application 61470927 · Apr 1, 2011
Provisional Application 61522659 · Aug 11, 2011
Related Publication 20140107330A1 · Apr 17, 2014
Cited By (1)
US 12,234,447